SAB Biotherapeutics, Inc., (SABS): Price and Financial Metrics
SABS Price/Volume Stats
| Current price | $1.81 | 52-week high | $5.01 |
| Prev. close | $1.84 | 52-week low | $1.00 |
| Day low | $1.80 | Volume | 2,411 |
| Day high | $1.92 | Avg. volume | 86,316 |
| 50-day MA | $1.60 | Dividend yield | N/A |
| 200-day MA | $2.52 | Market Cap | 16.81M |
SABS Stock Price Chart Interactive Chart >
SAB Biotherapeutics, Inc., (SABS) Company Bio
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH's ACTIV-2 protocol; and SAB-176, a fully-human polyclonal antibody therapeutic candidate designed to bind to type A and B viruses. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection; and SAB-181 for immune globulin (IgG) mediated diseases. It focuses on infectious diseases, such as COVID-19 and influenza, immune system disorders comprising type 1 diabetes, organ transplantation, and cancer. The company was founded in 2014 and is based in Miami Beach, Florida.
SABS Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SABS Price Returns
| 1-mo | 7.09% |
| 3-mo | 11.73% |
| 6-mo | -41.04% |
| 1-year | -36.27% |
| 3-year | -89.94% |
| 5-year | N/A |
| YTD | -52.30% |
| 2024 | -44.81% |
| 2023 | 16.55% |
| 2022 | -92.45% |
| 2021 | N/A |
| 2020 | N/A |